

Vamsi K Kota

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4928797/publications.pdf>

Version: 2024-02-01

93
papers

1,138
citations

471061

17
h-index

476904

29
g-index

99
all docs

99
docs citations

99
times ranked

1865
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology, Staging, and Management of Multiple Myeloma. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 3.	1.3	79
2	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
3	Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2018, 53, 826-831.	1.3	69
4	Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1128-1135.	2.0	59
5	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. <i>Journal of Hematology and Oncology</i> , 2018, 11, 143.	6.9	52
6	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 42.	3.4	51
7	Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3818.	1.8	48
8	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. <i>Leukemia</i> , 2022, 36, 1825-1833.	3.3	43
9	A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL). <i>Blood</i> , 2012, 120, 4317-4317.	0.6	40
10	Immunogenomic Gene Signature of Cell-Death Associated Genes with Prognostic Implications in Lung Cancer. <i>Cancers</i> , 2021, 13, 155.	1.7	38
11	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 466-471.e1.	0.2	37
12	A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression. <i>Scientific Reports</i> , 2017, 7, 12892.	1.6	31
13	Proposal of RT-PCR-Based Mass Population Screening for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019). <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1294-1299.	1.2	27
14	PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2. <i>MSphere</i> , 2022, 7, e0017922.	1.3	25
15	Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. <i>Leukemia Research</i> , 2018, 71, 27-33.	0.4	22
16	Acute leukemia with PICALM-MLL10 fusion gene: diagnostic and treatment struggle. <i>Cancer Genetics and Cytogenetics</i> , 2010, 202, 129-132.	1.0	21
17	Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link?. <i>Cancer</i> , 2015, 121, 872-875.	2.0	19
18	SalivaSTAT: Direct-PCR and Pooling of Saliva Samples Collected in Healthcare and Community Setting for SARS-CoV-2 Mass Surveillance. <i>Diagnostics</i> , 2021, 11, 904.	1.3	19

#	ARTICLE	IF	CITATIONS
19	Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 10-17.	0.5	18
20	Prognostic and therapeutic implications of extracellular matrix associated gene signature in renal clear cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 7561.	1.6	17
21	Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 4037.	1.7	16
22	Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. <i>JCO Oncology Practice</i> , 2021, 17, e497-e505.	1.4	14
23	Clinical Validation of a Sensitive Test for Saliva Collected in Healthcare and Community Settings with Pooling Utility for Severe Acute Respiratory Syndrome Coronavirus 2 Mass Surveillance. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 788-795.	1.2	14
24	Volasertib for AML: clinical use and patient consideration. <i>OncoTargets and Therapy</i> , 2015, 8, 1761.	1.0	13
25	A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent. <i>Leukemia Research</i> , 2019, 78, 45-51.	0.4	13
26	Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?. <i>Cancer</i> , 2017, 123, 2482-2488.	2.0	12
27	Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias. <i>Leukemia Research</i> , 2021, 111, 106690.	0.4	12
28	The safety of Bosutinib for the treatment of chronic myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1203-1209.	1.0	11
29	Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 480-487.	0.2	11
30	Clinical performance and utility of a comprehensive next-generation sequencing DNA panel for the simultaneous analysis of variants, TMB and MSI for myeloid neoplasms. <i>PLoS ONE</i> , 2020, 15, e0240976.	1.1	11
31	Infections of the lung: a predictive, preventive and personalized perspective through the lens of evolution, the emergence of SARS-CoV-2 and its pathogenesis. <i>EPMA Journal</i> , 2020, 11, 581-601.	3.3	11
32	Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1643.	1.7	11
33	Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. <i>Future Oncology</i> , 2017, 13, 395-407.	1.1	10
34	Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL. <i>Leukemia and Lymphoma</i> , 2019, 60, 1462-1468.	0.6	10
35	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	0.6	10
36	Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 765-770.	1.1	9

#	ARTICLE	IF	CITATIONS
37	Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2022, 114, 160-164.	3.0	9
38	Clinical validation of a multiplex PCR-based detection assay using saliva or nasopharyngeal samples for SARS-Cov-2, influenza A and B. <i>Scientific Reports</i> , 2022, 12, 3480.	1.6	9
39	Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD). <i>Blood</i> , 2015, 126, 1938-1938.	0.6	8
40	Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial. <i>Blood</i> , 2018, 132, 3005-3005.	0.6	7
41	Age and race distribution in patients in phase III oncology clinical trials. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 5977-5983.	0.0	7
42	Clinical and molecular assessment of an <sc>onco-immune</sc> signature with prognostic significance in patients with colorectal cancer. <i>Cancer Medicine</i> , 2022, 11, 1573-1586.	1.3	6
43	Acute Facial Paralysis and Otomastoiditis as Presenting Symptoms of Myeloid Sarcoma. <i>Otology and Neurotology</i> , 2015, 36, e104-e106.	0.7	5
44	Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 416-422.	0.5	5
45	Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial. <i>Blood</i> , 2018, 132, 1734-1734.	0.6	5
46	A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia. <i>American Journal of Case Reports</i> , 2019, 20, 10-14.	0.3	5
47	Effective optimization of SARS-CoV-2 laboratory testing variables in an era of supply chain constraints. <i>Future Microbiology</i> , 2020, 15, 1483-1487.	1.0	5
48	Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 1542.	1.0	5
49	Optimizing management of acute leukemia in community centers and when to refer. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 123-128.	0.9	5
50	Trends in the crossover of patients in phase III oncology clinical trials in the USA. <i>Ecancermedicalscience</i> , 2020, 14, 1142.	0.6	5
51	Complete Remission of Acute Myeloid Leukemia following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer. <i>Case Reports in Hematology</i> , 2016, 2016, 1-4.	0.3	4
52	Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e71-e73.	0.2	4
53	Rhabdomyolysis Following Initiation of Antiviral Therapy with Oseltamivir. <i>American Journal of Case Reports</i> , 2018, 19, 673-677.	0.3	4
54	Patientsâ€™ perspectives on the definition of cure in chronic myeloid leukemia. <i>Leukemia Research</i> , 2019, 80, 40-42.	0.4	4

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1921-1921.	0.6	4
56	Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 66-71.	0.1	4
57	Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation. <i>Hematology Reports</i> , 2017, 9, 7083.	0.3	3
58	Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome. <i>Case Reports in Oncology</i> , 2020, 13, 583-587.	0.3	3
59	Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates. <i>Blood</i> , 2019, 134, 2208-2208.	0.6	3
60	Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 3085-3094.	1.1	3
61	Pneumatosis Intestinalis in a Patient with Acute Promyelocytic Leukemia. <i>Case Reports in Hematology</i> , 2015, 2015, 1-3.	0.3	2
62	Recurrent Parotid Carcinosarcoma in an Asymptomatic Patient. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2016, 4, 232470961667659.	0.3	2
63	Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961769074.	0.3	2
64	Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA. <i>Hematology Reports</i> , 2019, 11, 7896.	0.3	2
65	Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-3.	0.2	2
66	A nationwide analysis of outcomes of stroke in hospitalized patients with essential thrombocythemia: 2006 to 2014. <i>American Journal of Blood Research</i> , 2020, 10, 76-81.	0.6	2
67	Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment. <i>Future Oncology</i> , 2022, , .	1.1	2
68	Rectovaginal Fistula as a Complication of Fecal Management System. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2019, 7, 232470961986936.	0.3	1
69	Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia. <i>Case Reports in Oncology</i> , 2020, 13, 534-537.	0.3	1
70	Sudden Blast Crisis After Excellent Initial Response in Chronic Myeloid Leukemia. <i>Cureus</i> , 2021, 13, e18368.	0.2	1
71	A successful model to decrease early deaths in acute promyelocytic leukemia (APL) through the use of a simplified algorithm and expert support.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18018-e18018.	0.8	1
72	Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS. <i>Blood</i> , 2011, 118, 2037-2037.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Congestive heart failure (CHF) in acute myeloid leukemia patients during induction.. Journal of Clinical Oncology, 2013, 31, 7105-7105.	0.8	1
74	A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US. Blood, 2013, 122, 5597-5597.	0.6	1
75	ATRA Availability on Formulary for the Treatment of APL Across Hospitals in the State of Georgia. Blood, 2015, 126, 4924-4924.	0.6	1
76	A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States. Blood, 2016, 128, 2793-2793.	0.6	1
77	Analysis of outcomes in hospitalized pregnant patients with acute myeloid leukemia. American Journal of Blood Research, 2020, 10, 68-75.	0.6	1
78	Trends in the crossover of patients in phase III oncology clinical trials in the USA. Ecancermedicalsecience, 2020, 14, 1142.	0.6	1
79	Serum Albumin As a Prognostic Factor for Overall Survival at 6-Months in Acute Myeloid Leukemia (AML). Blood, 2021, 138, 1226-1226.	0.6	1
80	A Rare Case of Epidural Myeloma Presenting as Recurrent Subdural Bleeding. Cureus, 2021, 13, e17794.	0.2	0
81	Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting. Blood, 2011, 118, 4468-4468.	0.6	0
82	Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies â€“ A Multicenter Analysis. Blood, 2011, 118, 313-313.	0.6	0
83	miRNA expression profiling of CD20+ plasma cell myeloma (PCM): Upregulation of miR-155 shedding new insight into disease biology and clinicopathologic behavior.. Journal of Clinical Oncology, 2012, 30, 8108-8108.	0.8	0
84	Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies â€“ A Multicenter Analysis. Blood, 2012, 120, 4409-4409.	0.6	0
85	Improving the Accuracy of BCR-ABL Transcript Quantitation: Pitfalls of Using a Common Standard for b3a2 and b2a2 Transcripts. Blood, 2012, 120, 4423-4423.	0.6	0
86	Decreasing early mortality (30-day) in APL patients with use of streamlined treatment guidelines and support from core group of experts.. Journal of Clinical Oncology, 2013, 31, 7091-7091.	0.8	0
87	A Nationwide Analysis of Outcomes of Stroke in Hospitalized Patients with Essential Thrombocythemia: 2006 to 2014. Blood, 2018, 132, 4293-4293.	0.6	0
88	Outcomes of Hospitalized Patients with Myocardial Infarction and Immune Thrombocytopenic Purpura: A Cross Sectional Study over 15 Years. Blood, 2018, 132, 4977-4977.	0.6	0
89	Outcomes of hospitalized patients with myocardial infarction and immune thrombocytopenic purpura: a cross sectional study over 15 years. American Journal of Blood Research, 2020, 10, 210-216.	0.6	0
90	Mortality trends in sickle cell patients. American Journal of Blood Research, 2020, 10, 190-197.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Central Line Associated Bloodstream Infection Rate Among Hematologic Malignant Patients Who Received Antimicrobial Prophylaxis in the Inpatient Setting. Blood, 2021, 138, 4390-4390.	0.6	0
92	The Increased Use of Diagnostic Studies over Time in Acute Myelogenous Leukemia Patients. Blood, 2021, 138, 4979-4979.	0.6	0
93	Rates of Neutropenic Fever in Patients with Hematologic Malignant Diseases with Central Venous Access. Blood, 2021, 138, 4953-4953.	0.6	0